General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview


  • Brachybacterium paraconglomeratum is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, oval-shaped bacterium. It has been detected in at least 3 gut microbiome compilation studies or metastudies. The DNA G+C content is 68.6%. Brachybacterium paraconglomeratum is probably a rare gut coloniser. (Takeuchi1995)



  • This organism has been recovered from human faeces. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. A possible gut commensal.

  • GENERAL CHARACTERISTICS (Takeuchi1995);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin; gelatin; starch; urea;
  • 🧂
  • Salt tolerance:
  • tolerates 2% salt; tolerates 3-5% salt; tolerates 7.5% salt;
  • pH
  • Acidity tolerance:
  • doesn't tolerate pH 5.0;
  • H+
  • Acid from carbohydrates usually produced:
  • L-arabinose; fructose; galactose; glucose; mannose; maltose; sucrose; adonitol; inositol; salicin;
  • Active enzymes:
  • alkaline phosphatase; acid phosphatase; catalase; esterase C4; esterase lipase C8; α-galactosidase; β-galactosidase; α-glucosidase; β-glucosidase; Leu arylamidase; α-mannosidase; pyrrolidine arylamidase; urease;

  • SPECIAL FEATURES (Takeuchi1995);
    Character Response
  • Metabolites produced:
  • H₂S; indole;
  • VP test:
  • not active
  • Nitrate:
  • reduced
  • NO3➔NO2:
  • reduced

  • Manichanh, C., Chapple, C. E., Frangeul, L., Gloux, K., Guigo, R., & Dore, J. (2008). A comparison of random sequence reads versus 16S rDNA sequences for estimating the biodiversity of a metagenomic library. Nucleic Acids Research, 36(16), 5180–5188.


  • Details


    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Actinobacteria Class:  Actinomycetia Order:  Micrococcales Family:  Dermabacteraceae Genus:  Brachybacterium Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Oval-shaped
    Health:  Unknown
    Source:  human faeces
    DNA G+C(%):  68.6
    NaCl 0.5-2%:  2(+)
    NaCl 3-5%:  3-5(+)
    NaCl >6%:  7.5(+)
    pH 4.2-5.9:  5.0(neg)
    Aesculin:  + Urea:  + Gelatin:  + Starch:  + Tween:  neg

    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  neg L-Arabinose:  + Fructose:  + Galactose:  + Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  neg Xylose:  neg Cellubiose:  w Lactose:  w Maltose:  + Melezitose:  w Melibiose:  w Sucrose:  + Trehalose:  neg Glycogen:  neg Adonitol:  + Inositol:  + Mannitol:  neg Sorbitol:  neg Xylitol:  neg Salicin:  +

    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  neg Catalase:  + Urease:  + α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg α-Mannosidase:  + LeuAA:  + PyrrolidAA:  + AlkalineP:  + AcidP:  + Esterase(C4):  + EstLip(C8):  + Lipase(C14):  neg

    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    H2S:  + Indole:  +

    References


    SPECIFIC REFERENCES FOR BRACHYBACTERIUM PARACONGLOMERATUM
  • Takeuchi1995 - Taxonomic Study of the Genus Brachybacterium: Proposal of Brachybacterium conglomeratum sp. nov., nom. rev., Brachybacterium paraconglomeratum sp. nov., and Brachybacterium rhamnosum sp. nov.
  • ...............................
  • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR BRACHYBACTERIUM PARACONGLOMERATUM
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • ...............................